Title page Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal PET and in-vitro study

[1]  W. Löscher,et al.  A Novel PET Protocol for Visualization of Breast Cancer Resistance Protein Function at the Blood–Brain Barrier , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  Xingrong Liu,et al.  Use of the Cassette-Dosing Approach to Assess Brain Penetration in Drug Discovery , 2012, Drug Metabolism and Disposition.

[3]  O. Langer,et al.  PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. , 2011, Current drug metabolism.

[4]  W. Löscher,et al.  Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. , 2011, Current pharmaceutical design.

[5]  Oliver Langer,et al.  Approaches using molecular imaging technology -- use of PET in clinical microdose studies. , 2011, Advanced drug delivery reviews.

[6]  W. Löscher,et al.  A Novel Positron Emission Tomography Imaging Protocol Identifies Seizure-Induced Regional Overactivity of P-Glycoprotein at the Blood–Brain Barrier , 2011, The Journal of Neuroscience.

[7]  Donald W. Miller,et al.  Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein. , 2011, Bioorganic & medicinal chemistry.

[8]  M. Gottesman,et al.  The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). , 2011, ACS chemical neuroscience.

[9]  Ming-Rong Zhang,et al.  Evaluation of Limiting Brain Penetration Related to P-glycoprotein and Breast Cancer Resistance Protein Using [11C]GF120918 by PET in Mice , 2011, Molecular Imaging and Biology.

[10]  W. Löscher,et al.  Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy. , 2010, Current topics in medicinal chemistry.

[11]  S. Bates,et al.  ABC transporters: unvalidated therapeutic targets in cancer and the CNS. , 2010, Anti-cancer agents in medicinal chemistry.

[12]  W. Löscher,et al.  Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. , 2010, Bioorganic & medicinal chemistry.

[13]  G. M. Pollack,et al.  Examination of the ability of the nasal administration route to confer a brain exposure advantage for three chemical inhibitors of P-glycoprotein. , 2010, Journal of pharmaceutical sciences.

[14]  H. Kusuhara,et al.  Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone , 2010, Journal of Pharmacology and Experimental Therapeutics.

[15]  Ming-Rong Zhang,et al.  Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET , 2010, Annals of nuclear medicine.

[16]  W. Löscher,et al.  Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. , 2009, Journal of medicinal chemistry.

[17]  A. Schinkel,et al.  Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. , 2009, Molecular interventions.

[18]  Christin Müller,et al.  Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. , 2009, Journal of medicinal chemistry.

[19]  P. Herscovitch,et al.  P-Glycoprotein Function at the Blood–Brain Barrier Imaged Using 11C-N-Desmethyl-Loperamide in Monkeys , 2008, Journal of Nuclear Medicine.

[20]  Wolfgang Löscher,et al.  Several major antiepileptic drugs are substrates for human P-glycoprotein , 2008, Neuropharmacology.

[21]  Michael Wiese,et al.  Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). , 2008, Bioorganic & medicinal chemistry.

[22]  Jos H Beijnen,et al.  P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan , 2007, Clinical Cancer Research.

[23]  W. Löscher,et al.  Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein , 2007, Neuropharmacology.

[24]  W. Löscher,et al.  Valproic Acid Is Not a Substrate for P-glycoprotein or Multidrug Resistance Proteins 1 and 2 in a Number of in Vitro and in Vivo Transport Assays , 2007, Journal of Pharmacology and Experimental Therapeutics.

[25]  J. Seelig,et al.  Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity. , 2006, Biophysical journal.

[26]  R. Kim,et al.  Differential in Vivo Sensitivity to Inhibition of P-glycoprotein Located in Lymphocytes, Testes, and the Blood-Brain Barrier , 2006, Journal of Pharmacology and Experimental Therapeutics.

[27]  Wolfgang Löscher,et al.  Drug resistance in brain diseases and the role of drug efflux transporters , 2005, Nature Reviews Neuroscience.

[28]  S. Bates,et al.  Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.

[29]  O. van Tellingen,et al.  Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. , 2003, Cancer research.

[30]  H. Coley,et al.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[31]  J. Schellens,et al.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.

[32]  F H Hausheer,et al.  Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  T. Litman,et al.  Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. , 1999, Cancer letters.

[34]  C. Higgins,et al.  The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein , 1999, British journal of pharmacology.

[35]  J. Beijnen,et al.  Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. , 1997, The Journal of clinical investigation.

[36]  T. Tsuruo,et al.  Potentiation of the reversal activity of SDZ PSC833 on multi‐drug resistance by an anti‐p‐glycoprotein monoclonal antibody MRK‐16 , 1996, International journal of cancer.

[37]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.

[38]  W. Löscher,et al.  A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  A. Smith,et al.  Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. , 1998, Journal of the National Cancer Institute.

[40]  Hitoshi Sato,et al.  Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats , 1996, Cancer Chemotherapy and Pharmacology.

[41]  D. Cohen,et al.  Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein. , 1995, Oncology research.